Authoritative Research Revises Anti-Aging Industry Consensus: Whole-Blood NAD+ Lacks Value as an Aging Biomarker

A multinational cohort study published in Nature Metabolism in 2026 has upended conventional perceptions in the field of NAD+ metabolism, delivering pivotal references for the NAD+ supplement and aging testing industries.

The research team established a highly precise ultra-high-performance liquid chromatography-high-resolution mass spectrometry detection protocol, covering seven independent population cohorts with more than 300 participants, including ordinary individuals across age groups, professional athletes, and an intervention group of frail elderly adults. Consistent data across all cohorts verified that whole-blood NAD+ concentrations in the human body do not decline naturally with advancing age, nor can they be altered by lifestyle interventions such as regular exercise and high-protein diets. Only exogenous supplementation with the NR nucleoside precursor is capable of markedly elevating circulating blood NAD+ levels.

The team further validated that previously observed "age-associated declines in NAD+" were largely attributable to pre-analytical errors stemming from repeated freeze-thaw cycles and room-temperature storage of specimens. Pre-preservation with methanol can drastically mitigate metabolite degradation and reduce false-positive experimental results.

Industry analysts comment that these findings invalidate the core marketing narratives prevalent across the market, confirming that blood NAD+ testing cannot be adopted to assess the degree of biological aging. Nevertheless, the study does not negate the physiological functions of NAD+ in visceral organs and muscle tissue. Going forward, the clinical evaluation of NAD+-related health supplements and aging screening products will require upgraded testing specimens and refined indicator evaluation frameworks.

FOR DETAIL:  https://doi.org/10.1038/s42255-026-01537-5

Article from: